Literature DB >> 17229643

Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems.

Amir Osman Abdalla1, Lotta Hansson, Ingrid Eriksson, Barbro Näsman-Glaser, Eva D Rossmann, Hodjattallah Rabbani, Håkan Mellstedt, Anders Osterborg.   

Abstract

Anti-idiotypic T cells were analyzed in myeloma patients (n=18) vaccinated with idiotypic protein together with the adjuvant cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or interleukin-12 (IL-12). In the group given IL-12/GM-CSF, 78% developed idiotype specific T cells as compared to 22% in the group given only IL-12 (proliferation/ELISPOT assays) (p<0.05). The percentage of immune-responding patients increased when quantitative real time polymerase chain reaction assays for cytokines were included. A predominance of a Th1 (IFN-gamma/TNF-alpha) immune response was noted in the IL-12 group while a Th2 (IL-5) response prevailed in the IL-12/GM-CSF group (p=0.053). Application of multiple read-out systems improved the characterization of the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229643     DOI: 10.3324/haematol.10095

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

1.  Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.

Authors:  O A Haabeth; A Tveita; M Fauskanger; K Hennig; P O Hofgaard; B Bogen
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

Review 2.  Immunotherapy of cancer by IL-12-based cytokine combinations.

Authors:  Jonathan M Weiss; Jeff J Subleski; Jon M Wigginton; Robert H Wiltrout
Journal:  Expert Opin Biol Ther       Date:  2007-11       Impact factor: 4.388

3.  Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.

Authors:  Katy J McCann; Rosemary Godeseth; Lindsey Chudley; Ann Mander; Gianfranco Di Genova; Paul Lloyd-Evans; Jonathan P Kerr; Vladimir B Malykh; Matthew W Jenner; Kim H Orchard; Freda K Stevenson; Christian H Ottensmeier
Journal:  Cancer Immunol Immunother       Date:  2015-05-16       Impact factor: 6.968

4.  Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model.

Authors:  Tim Roehnisch; Cornelia Then; Wolfgang Nagel; Christina Blumenthal; Todd Braciak; Mariel Donzeau; Thomas Böhm; Carole Bourquin; Fuat Oduncu
Journal:  J Transl Med       Date:  2013-10-23       Impact factor: 5.531

5.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Authors:  Michael Boyiadzis; Michael R Bishop; Rafat Abonour; Kenneth C Anderson; Stephen M Ansell; David Avigan; Lisa Barbarotta; Austin John Barrett; Koen Van Besien; P Leif Bergsagel; Ivan Borrello; Joshua Brody; Jill Brufsky; Mitchell Cairo; Ajai Chari; Adam Cohen; Jorge Cortes; Stephen J Forman; Jonathan W Friedberg; Ephraim J Fuchs; Steven D Gore; Sundar Jagannath; Brad S Kahl; Justin Kline; James N Kochenderfer; Larry W Kwak; Ronald Levy; Marcos de Lima; Mark R Litzow; Anuj Mahindra; Jeffrey Miller; Nikhil C Munshi; Robert Z Orlowski; John M Pagel; David L Porter; Stephen J Russell; Karl Schwartz; Margaret A Shipp; David Siegel; Richard M Stone; Martin S Tallman; John M Timmerman; Frits Van Rhee; Edmund K Waller; Ann Welsh; Michael Werner; Peter H Wiernik; Madhav V Dhodapkar
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

Review 6.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

7.  Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.

Authors:  Tim Roehnisch; Cornelia Then; Wolfgang Nagel; Christina Blumenthal; Todd Braciak; Mariel Donzeau; Thomas Böhm; Michael Flaig; Carole Bourquin; Fuat S Oduncu
Journal:  J Transl Med       Date:  2014-05-09       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.